{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-065289","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.558173+00:00","generated_at":"2026-06-18T07:26:25.958819+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan Oncology reports Q4 net loss of $27.1M; licenses CLN-418; cash runway into 2026","bullets":["Cash and investments $550.1M as of Dec 31, 2022; cash runway expected into 2026.","Licensed U.S. rights to CLN-418 from Harbour Biomed for $25M upfront, up to $563M milestones plus royalties.","Q4 net loss before noncontrolling interest $27.1M; full-year net income $109.2M due to gain on sale of Cullinan Pearl.","IND clearance for CLN-978 (CD19xCD3) in Jan 2023; IND filed for CLN-617 (IL-12/IL-2) in Feb 2023.","Initial clinical data for CLN-049 and CLN-619 expected mid-2023; pivotal study for zipalertinib initiated Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-065289","json":"https://secwatch.observer/filing/0001193125-23-065289.json","markdown":"https://secwatch.observer/filing/0001193125-23-065289.md","text":"https://secwatch.observer/filing/0001193125-23-065289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/0001193125-23-065289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/d481993d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:26:25.958819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9a85f5c80c025e56bc2484125a62ac42dc84a6d","claim":"Cullinan Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: net income 27.1 million.","evidence_excerpt":"Net loss (before items attributable to noncontrolling interest) for the fourth quarter of 2022 was $27.1 million, compared with net loss of $24.9 million for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/0001193125-23-065289-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"27.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}